Analyses of purified tumor-infiltrating CD45+ cells indicated that Lov treatment increased mRNA levels for M1 markers, which was statistically significant for IFNγ and IL-1β, whereas it downregulated M2-like markers (with significant differences for IL-10, CD206 and CCL22; Fig. 6F). The gene discussed is IL1B; the disease is neoplasm.